Bristol-Myers Squibb Company / Exelixis, Inc. (TGR5 + ROR programs)
2010 · Licensing/Option · $565M · Complete
Announcement Sentiment
63
Positive
Exelixis licensed exclusive TGR5 agonist program ($250M milestones) and entered ROR antagonist collaboration ($255M milestones) with BMS for total $60M combined upfront. Followed XL184 codevelopment termination.